News Digest for May 2019

Posted on: 2019-07-12 10:28:07

May 2, 2019

Checkpoint Therapeutics today announced positive interim results from its ongoing multicenter Phase 1 clinical trial of cosibelimab (formerly referred to as CK-301).  (here)

Retinoblastoma (RB) constrains lineage fidelity and multiple stages of tumour progression and metastasis (here)

Gene Editing Institute Inching Toward CRISPR Clinical Trials in Lung Cancer (here)

AstraZeneca’s experimental MEK 1/2 inhibitor selumetinib has racked up its share of trial failures, most recently in KRAS mutation-positive non-small cell lung cancer (NSCLC) and thyroid cancer. But the company is turning the disappointments into an opportunity, teaming up with researchers at the Babraham Institute in the United Kingdom to try to determine how cancer cells become resistant to the treatment. (here)


The Lung Cancer Research Foundation and Pfizer Announce Collaboration in Lung Cancer Research (here)

Dr. Konduri Discusses Promise of NGS Testing in NSCLC (here)

Comparative study of the PD-L1 expression and CD8+ tumor-infiltrating lymphocyte between surgically resected and matched re-biopsy specimens in recurrent non-small cell lung cancer (here)

A platform for rapidly profiling mutations and gene expression offers valuable insights into cancer biology (here)

US researchers have replicated previously described associations between patient and tumor characteristics and clinical outcomes using routinely collected clinical and genomic data for patients with non-small-cell lung cancer (NSCLC).  Gaurav Singal (Foundation Medicine Inc, Cambridge, Massachusetts) and colleagues say that their findings “demonstrate the feasibility of creating a clinicogenomic database derived from routine clinical experience and provide support for further research and discovery evaluating this approach in oncology.” (here)

Activity and molecular targets of pioglitazone via blockade of proliferation, invasiveness and bioenergetics in human NSCLC (here)

May 3, 2019

The rationale for frontline chemoimmunotherapy in stage IV nonsquamous non–small cell lung cancer (NSCLC), now made evident by several phase III trials, stems from its synergistic activity, stimulatory effects on neoantigens, and tolerable safety profile.  Although chemotherapy was initially considered to be immunosuppressive, its addition to immunotherapy has been shown to increase tumor mutational burden, triggering greater expression and release of neoantigens, therein inciting an immune response, explained Claude Denham, MD, in a presentation during the 2019 OncLive® State of the Science Summit™ on Non–Small Cell Lung Cancer.  (here)

May 5, 2019

Rolf A. Stahel, MD, Zurich, discusses treatment sequencing in stage IV non–small cell lung cancer (NSCLC). Over the last few years, sequencing in advanced NSCLC has changed, Stahel says. It was a generally simple paradigm a few years ago of frontline chemotherapy followed by an alternative chemotherapy agent in the second-line setting. Because the field has shifted toward single-agent immunotherapy or chemoimmunotherapy in the frontline setting, the approach has shifted in the second-line setting. (here)

Alfredo Addeo, MD, Geneva, discusses the need for effective biomarkers in non–small cell lung cancer (NSCLC). In general, the field of NSCLC has improved quite remarkably over the last few years. This is particularly true for patients with EGFR and ALK driver mutations, where targeted therapies have improved survival by many months if not years. The rise of immunotherapy has probably been the most significant advancement in this space, leading to increased overall and progression-free survival. (here)

Umberto Malapelle, PhD, Naples, discusses unanswered questions regarding the role of tumor mutational burden (TMB) in non–small cell lung cancer (NSCLC).  Malapelle explained that TMB is a fascinating biomarker. TMB has solid rationale for use in terms of its predictive value of response to immunotherapy. With that being said, Malapelle notes it is not quite ready for primetime use. Notably, researchers need more overall survival data with this approach in NSCLC and other solid tumors. To date, only progression-free survival data has been published.  (here)

Function of Human Tumor-Infiltrating Lymphocytes in Early Stage Non-Small Cell Lung Cancer (here)

May 8, 2019

You-cai Zhu, MD, PhD, Zhejiang Rongjun Hospital, discusses primary resistance to osimertinib (Tagrisso) in EGFR-mutant non–small cell lung cancer (NSCLC).  Zhu presented data from a Chinese trial that examined a total of 117 patients with stage IIIb/IV EGFR-T790M NSCLC. Among those treated with osimertinib, 82.91% developed acquired resistance and 7.69% had primary resistance to the agent. According to the baseline specimens, 3 patients had MET amplification, 1 patient had BCL2L11 loss, 1 patient had ERBB2 amplification, 1 patient had a PTEN mutation, and 1 patient had an EZH2 mutation. Two patients had unknown status, suggesting that primary resistance to EGFR-T790M may be highly heterogenous, concludes Zhu.  (here)


PDC*line Pharma obtains authorization to launch phase I/II trial of its cancer vaccine (PDC*lung01) in non-small cell lung cancer. (here)

Survival and intracranial control outcomes of whole-brain radiotherapy (WBRT) alone versus WBRT plus a radiotherapy boost in non-small-cell lung cancer with brain metastases: a single-institution retrospective analysis.  //  WBRT plus RTB significantly improved iLPFS compared with WBRT alone, especially in patients without EGFR-TKI treatment. However,there were no significant differences in iRPFS or OS between the two groups. Patients treated with EGFR-TKIs may not benefit from WBRT plus RTB. (here)

Joshua Bauml, MD, University of Pennsylvania, discusses the use of locally ablative therapy in patients with oligometastatic non–small cell lung cancer (NSCLC).  Retrospective data first addressed the question of the prevalence of this patient population. Bauml says that oligometastatic disease makes up 7% of patients with NSCLC, which is as rare as ALK-positive NSCLC. Data have examined the use of locally ablative therapy, which consists of surgery and radiation to all metastatic sites, and have shown that this approach improves outcomes for patients compared with historical controls. More recently, randomized trials have confirmed this benefit. (here)

Thousands of new patients are now able to enroll in Lung Cancer Master Cancer Protocol (Lung-MAP), a National Cancer Institute (NCI) trial. Criteria have been expanded to allow patients with all types of non-small cell lung cancer (NSCLC).  (here)

May 9, 2019

Stereotactic body radiotherapy safe, effective for tumor control in centrally located NSCLC (here)

Phase II Study of S-1 and Paclitaxel Combination Therapy in Patients with Previously Treated Non-Small Cell Lung Cancer (here)

Researchers at Seoul National University Hospital (SNUH) have found that cancer cells in the tumor secrete certain substances to change the distribution of immune cells to make a cancerous environment. // As the interaction of cancer cells and immune cells in the tumor affects the survival of the tumor, it is essential to understand tumor microenvironment to develop such immunotherapies.  //  The team, led by Professor Chung Doo-hyun analyzed cancerous microenvironment using cancer tissue from 80 non-small cell lung cancer patients at SNUH. It found lung cancer cells secrete interleukin-23 and induce changes in the subpopulation of congenital lymphocyte cells, which in turn, secrete interleukin-17 and promote tumor growth.  (here)

Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study (here)

May 10, 2019

Phase II trial of S-1 plus cisplatin combined with bevacizumab for advanced non-squamous non-small cell lung cancer (TCOG LC-1202) (here)

Bristol-Myers Squibb has a fresh Phase III setback to report today on its all-important PD-1 drug Opdivo. The pharma giant says that their drug combined with radiation failed to significantly improve the overall survival rate of glioblastoma patients compared to a control group receiving chemo plus radiation. (here)

A lot of the initial diagnostic work-up of lung cancer specimens is in peripheral hospitals, district general hospitals, where nonexpert pathologists are required to make an initial diagnosis. And because they lack the expertise and the confidence, they often do unnecessary and extensive immunochemistry to classify the tumor, to exclude the possibility, even if it’s minimal that the tumor is metastatic and so on. And this uses tissue, so that when those specimens are referred centrally for the genomic profiling—which these days is the crucial information—there is insufficient for analysis. (here)

Reflex testing essentially means that the pathologist organizes testing profiling of the specimen at the time of diagnosis. In other words, as soon as the pathologist knows that there is non–small cell carcinoma in the biopsy, he or she can then start the ball rolling with the profiling. And that has huge advantages, of course. It means that the testing is done very quickly. It means the inflammation is integrated. It means it’s ready for the oncologist usually by the time of the first meeting of the tumor board or the multidisciplinary team, and it permits forward planning.  (here)

Dacomitinib is an important first- line agent in EGFR-mutated non-small-cell lung cancer in otherwise fit patients whose toxicities can be well managed. (here)

May 13, 2019

This study unveils the role of low levels of Interferon-γ (IFN-γ) in conferring tumor stemness and elucidates the distinct signaling pathways activated by IFN-γ in a dose-dependent manner, thus providing new insights into cancer treatment, particularly for patients with low expression of IFN-γ in the TME. (here)

Cantargia AB (publ) and Patheon Biologics B.V. (part of ThermoFischer Scientific) have signed an agreement regarding future production of the antibody CAN04 (nidanilimab). CAN04 is currently in phase IIa clinical development for non-small cell lung cancer and pancreatic cancer. Hereby, Cantargia secures additional production capacity for future clinical trials.  (here)

Neon Therapeutics Reports First Quarter 2019 Financial Results and Provides Clinical Update GlobeNewswire.  Advancing a class-leading position in neoantigen-based therapies with ongoing progress across its multiple clinical-stage programs, pre-clinical pipeline and bioinformatics engine.  Expect to report in July top-line clinical results, including 12-month follow-up, from NT-001 trial of personal neoantigen vaccine NEO-PV-01 in metastatic melanoma, non-small cell lung and bladder cancers (here)

Is a Five-Fraction SBRT Schedule Tolerable in Patients With Centrally Located NSCLC?  (here)

Safety, tolerability, and pharmacokinetics of simotinib, a novel specific EGFR tyrosine kinase inhibitor, in patients with advanced non-small cell lung cancer: results of a phase Ib trial  (here)

Assessment of blood tumor mutational burden as a potential biomarker for immunotherapy in patients with non–small cell lung cancer with use of a next-generation sequencing cancer gene panel  (here)

Identification of novel biomarkers and candidate small molecule drugs in non-small-cell lung cancer by integrated microarray analysis (here)

May 15, 2019

Case report.  A novel approach for salvage treatment of non-small-cell lung cancer: percutaneous CT fluoroscopy-guided permanent seed brachytherapy for salvage treatment of lung cancer: long-term results of a case series (here)

Vaccinex Announces Poster Presentations at the 2019 ASCO Annual Meeting.  Preliminary Results From CLASSICAL-Lung, a Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer (NSCLC)  (here)

Dr. Bruce Johnson (DFCI). How a NSCLC Pioneer Helped Unravel the Mysteries of EGFR.  (here)

Growing scientific evidence supports liquid biopsy as a valuable tool for monitoring treatment response in patients with cancer. (here)

IO Biotech Initiates Global Phase 2 Portion of Clinical Trial For T-win® Immunotherapy in Non-small Cell Lung Cancer (here)

May 16, 2019

Ramucirumab - Data Presentations at ASCO 2019 Highlight Lilly's Targeted Approach to Developing Treatments for Patients Living with Cancer (here)

Daiichi Sankyo Data Presentations at 2019 ASCO Annual Meeting Highlight Depth of ADC Pipeline and Promises of Oncology Portfolio (here)

MiR-449a regulates the cell migration and invasion of human non-small cell lung carcinoma by targeting ADAM10 (here)

May 17, 2019

The core of Yuhan’s announcement at ASCO this year is on the latest results for its phase 1 and 2 clinical trials into Lazertinib, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), in patients with EGFR-TKI resistant non-small cell lung cancer. (here)

Pending overall survival (OS) data from the phase III FLAURA trial, osimertinib (Tagrisso) may be the preferred frontline treatment for patients with EGFR-mutant non–small cell lung cancer (NSCLC), said Lyudmila A. Bazhenova, MD. However, treatment beyond progression on the agent will require more consideration, especially in the face of heterogenous resistance mechanisms.(here)

Comparing Results for 80 mg versus 160 mg Osimertinib in Advanced EGFR+ NSCLC (here)

According to results from a phase IIIb interim analysis, afatinib (Gilotrif) demonstrated a predictable and manageable toxicity profile and promising efficacy in patients with EGFR mutation-positive non–small cell lung cancer (NSCLC). The findings were consistent with data from the LUX-Lung (LL) 3/6 trials that compared frontline afatinib to standard chemotherapy in the same patient population. (here)

During a recent Targeted Oncology live case-based peer perspectives presentation, Paul K. Paik, MD, explained to a group of physicians the treatment considerations and decisions he makes when seeing a patient with non–small cell lung cancer (NSCLC). Paik, an associate attending physician and clinical director of the Thoracic Oncology Service at Memorial Sloan Kettering Cancer Center, reviewed treatment options when discussing the case studies of 2 patients with metastatic NSCLC. (here)

May 18, 2019

Now, a new study from researchers at Harvard Medical School have shed light on the greens’ health benefits by demonstrating that targeting a gene, known as WWP1, with an ingredient found in broccoli, suppressed tumor growth in cancer-prone lab animals. The results are published in Science in a paper titled “Reactivation of PTEN tumor suppressor for cancer treatment through inhibition of a MYC-WWP1 inhibitory pathway.


Tumor growth in most lung cancer cells depends on the availability of heme, according to the results of a recent study published in Cancer Research. Of note, heme represents 97% of the body’s functional iron pool, and iron plays a role in tumor formation and progression.  “Targeting heme flux and function offers a potential strategy for developing therapies for lung cancer,” wrote the authors, led by Sagar Sohoni, Department of Molecular and Cell Biology, University of Texas at Dallas, Richardson, TX. (here)

May 19, 2019

Trials with people with newly-diagnosed colorectal and non-small cell lung cancer suggest that whole body MRI could reduce the time it takes to diagnose the stage of cancers. (here)

May 21, 2019

Patent ( BOEHRINGER INGELHEIM): The invention describes anti - cancer therapies comprising using a 3G - EGFR inhibitor and an irreversible EGFR TKI , each as described herein . (here)


Autoimmune Skin Toxicities Linked With Response to Immunotherapy in Lung Cancer (here)

Dr. Nadler on the Impact of Immunotherapy in Squamous NSCLC (here)

Efficacy and safety of programmed death 1 inhibitors in patients with advanced non-small cell lung cancer: a meta-analysis (here)

Frontline Afatinib Shows Promise in EGFR+ NSCLC (here)

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial (here)

HEATR1 modulates cell survival in non-small cell lung cancer via activation of the p53/PUMA signaling pathway (here)

May 22, 2019

The upfront use of next-generation sequencing (NGS) was associated with a substantial cost savings compared with other types of genetic testing, according to a computer modeling analysis of patients with metastatic non–small-cell lung cancer (NSCLC).  “Targeted therapies have been demonstrated to significantly improve treatment response and progression-free survival,” wrote study authors led by Nathan A. Pennell, MD, PhD, of the Cleveland Clinic in Ohio. “Therefore, it is important to identify patients with specific genomic alterations to individualize treatment and optimize outcomes.”  (here)

Results of the phase III KEYNOTE-189 and IMpower150 trials showed a profound survival benefit in patients with advanced nonsquamous non–small cell lung cancer (NSCLC), when pembrolizumab (Keytruda) and atezolizumab (Tecentriq), respectively, were added to standard chemotherapeutic backbones. Now, selection between the 2 regimens must be based on individual risk factors and comorbidities, explained Bing Xia, MD.  (here)

May 24, 2019

Tumor Treating Fields.  Novocure is conducting later-phase trials in pancreatic, liver, ovarian and non-small cell lung cancers as well as in brain metastases.  (here)

Corey J. Langer, MD, director, Thoracic Oncology, University of Pennsylvania, discusses the use of next-generation sequencing (NGS) in non–small cell lung cancer (NSCLC).  With a number of actionable mutations in NSCLC, it is critical to do NGS, Langer says. The biggest challenge with NGS is that the turnaround time is still 2 weeks, sometimes as long as a month. If a patient is particularly symptomatic, a physician might not be able to wait that long to start therapy, says Langer. In that case, chemotherapy and immunotherapy is typically administered, he adds.  (here)

Researcher from the Abramson Cancer Center at University of Pennsylvania have demonstrated that adding bevacizumab (Avastin®; Genentech/Roche) to carboplatin-pemetrexed when treating patients with advanced non-squamous non-small cell lung cancer (NSCLC) results in a modest but consistent survival benefit. (here)

In non–small cell lung cancer (NSCLC), KRAS G12 mutations have been historically difficult to target, and research efforts dedicated to the development of effective targeted therapies for NRG1 fusions have not been successful. However, several biopharmaceutical companies are in the early stages of addressing that challenge, explained Sai-Hong I. Ou, MD, PhD (UCal/Irvine).  “KRAS has been a mutation that we have had difficulty targeting for the last 30 to 40 years. In the last half year, however, 2 companies have made a direct KRAS G12C inhibitor,” said Ou. “On average, NRG1 fusions occur in about 0.2% to 0.3% of cancers. They’re [extremely] rare, but given the success of targeting NTRK fusions, we'll overcome the challenge of finding these NRG1 fusions.”  In addition to these alterations, Ou explained that EGFR exon 20 insertions and HER2 transmembrane domain mutations, albeit rare, are likely to gain therapeutic traction in the coming years as well. (here)

Osimertinib (Tagrisso) at a once-daily dose of 80 mg demonstrated similar signs of activity, as well as a clinically meaningful benefit in patients with EGFR T790M–positive advanced non–small cell lung cancer (NSCLC) who had radiographically detected leptomeningeal metastases (LM) compared with the 160-mg dose observed in the AURA LM trial. (here)

KRAS and Immune Checkpoint Inhibitors—Serendipity Raising Expectations (here)

Is routine baseline brain imaging needed for all newly diagnosed non-small-cell lung cancer patients?  (here)

Mark Socinski, MD, explained to a group of physicians at a recent Targeted Oncology live case-based peer perspectives presentation, the treatment considerations and decisions he makes when seeing patients with non–small cell lung cancer (NSCLC) in the clinic. Socinski, the executive medical director of AdventHealth Cancer Institute, reviewed treatment options based on the case scenarios of 2 patients with advanced nonsquamous NSCLC.  (here)

OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE), today announced that it will host a Key Opinion Leader (KOL) meeting on novel treatments in non-small cell lung cancer (NSCLC) on May 30th in New York City.  (here)

May 25, 2019

Treatment of uncommon EGFR mutations in non-small cell lung cancer: new evidence and treatment (here)

Luminespib plus pemetrexed in patients with non-squamous non-small cell lung cancer (here)

Articles in Journal of Thoracic Oncology (here)

May 28, 2019

FDA has approved Novocure's tumor treating fields delivery system NovoTTF-100L for use in patients with malignant pleural mesothelioma (MPM). (here)

Impact of EGFR genotype on the efficacy of osimertinib in EGFR tyrosine kinase inhibitor-resistant patients with non-small cell lung cancer: a prospective observational study (here)

Lunit today announced an abstract presentation of its AI precision medicine research portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting 2019.  The accepted abstract highlights the feasibility of AI-based biomarker in metastatic non-small cell lung cancer, based on the H&E analysis that predicts response to immune checkpoint inhibitors (ICI).  (here)

Poziotinib ZENITH20 Trial.  Spectrum Pharmaceuticals, Inc. (SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today the full enrollment of cohort 2 (N = 87) for previously treated non-small cell lung cancer (NSCLC) patients with HER2 exon 20 insertion mutations.  (here)

Last Patient Enrolled in the Phase 2 Trial with Transgene’s TG4010 + Nivolumab + Chemotherapy for the First-Line Treatment of Advanced Lung Cancer (NSCLC)  (here)


We conclude that PFKFB3 has a key role in mediating glucose metabolism and survival of NSCLC cells in response to EGFR signaling. These results support the potential clinical utility of using PFKFB3 inhibitors in combination with EGFR-TKIs to manage NSCLC. (here)

Recommended Settings for Durvalumab Treatment Insights From: Nicolas Girard, MD, Curie Institute (here)

New research from the Abramson Cancer Center at the University of Pennsylvania, published in the May 2019 issue of the Journal of the National Comprehensive Cancer Network uses a large, real-world dataset to demonstrate there is a modest but consistent survival benefit associated with adding bevacizumab to carboplatin-pemetrexed when treating advanced non-squamous non-small cell lung cancer. (here)

The Changing Landscape in Molecular Testing.  Insights From: John G. Gosney, MD, FRCPath, Royal Liverpool and Broadgreen University Hospital NHS Trust  (here)

May 29, 2019

Bio-Techne today announced the publication of a recent validation study demonstrating that the proprietary exosome-based liquid biopsy tests from Bio-Techne's Exosome Diagnostics brand may be used to assess the mutational status of the Epidermal Growth Factor Receptor (EGFR) gene in patients with non-small cell lung cancer (NSCLC).  (here)


Sihuan Pharmaceutical, the largest cardio-cerebral vascular ("CCV") drug manufacturer in China's prescription drug market, announced the third generation of EGFR inhibitor XZP-5809, a Category 1 innovative drug developed by the Group, has been granted drug clinical trial approval by the National Medical Products Administration of the PRC. The New Drug is a Category 1 innovative drug of the PRC developed by the Group.  The New Drug is a novel third-generation epithelial growth factor receptor-tyrosine kinase inhibitor (''EGFR-TKI'') that has strong targeting capability, and can be taken orally. It features innovative structure, established mechanism and irreversible binding to EGFR. The New Drug has better selection with higher activity against gene-mutation EGFR and lower activity against wild-type EGFR.  (here)


New Therapies Are Coming for Lung Cancer With Rare Mutations (here)

Nivolumab plus ipilimumab combination therapy for the first-line treatment NSCLC: evidence to date.  In this review, we discuss the efficacy of nivolumab and ipilimumab in advanced NSCLC patients as well as the clinical utility of tumor mutational burden in the efficacy of this combination. Ongoing clinical trials with nivolumab and ipilimumab, and the efficacy of this combination in subgroups of NSCLC patients, such as elderly patients and patients with brain metastases, are also discussed. (here).  

Jeffrey M. Clarke, MD, Duke Cancer Institute, compares EGFR TKIs in EGFR-positive non–small cell lung cancer.  Both osimertinib (Tagrisso) and dacomitinib (Vizimpro) are FDA approved for the frontline treatment of this patient population, but osimertinib has emerged as the preferred agent in this setting. Clarke says that osimertinib, a third-generation EGFR TKI, has a longer median progression-free survival and a more favorable toxicity profile than dacomitinib, a second-generation irreversible pan-HER TKI.  (here)

Scott J. Antonia, MD, Duke University School of Medicine, discusses the promise of immunotherapy in patients with non–small cell lung cancer (NSCLC).  When immunotherapy was initially tested in stage IV disease, physicians were doubtful that it would result in a clinical benefit. However, NSCLC appears to be the second most immunogenic tumor behind melanoma. One of the most exciting aspects of immunotherapy is that it yields durable responses and potential long-term survival in addition to improvements in median overall survival, says Antonia. In a study of patients with metastatic NSCLC, 15% of those treated with immunotherapy were alive at 5 years, he adds.  (here)

May 31, 2019

French biopharmaceutical firm, Transgene SA has recently announced that it has enrolled the last patient in its Phase 2 trial for evaluating TG4010 in conjunction with Opdivo® and chemotherapy as a first-line treatment for advanced non-squamous non-small cell lung cancer (NSCLC) with low or no expression of PD-L1 by the tumor cells. (here)

First-line atezolizumab–chemotherapy an option for nonmutated metastatic NSCLC  (here)

Lyudmila A. Bazhenova, MD, University of California, San Diego, discusses sequencing beyond progression on osimertinib (Tagrisso) in EGFR-mutant non–small cell lung cancer (NSCLC). (here)


Inhibition of tumor metastasis by targeted daunorubicin and dioscin codelivery liposomes modified with PFV for the treatment of non-small-cell lung cancer (here)

Serum hepatitis B viral (HBV) DNA is a predictive biomarker for survival in non-small cell lung cancer patients with chronic HBV infection (here)

The discovery of actionable mutations and the increasing importance of immunotherapy has created a brighter outlook for patients with non–small cell lung cancer (NSCLC), but a better understanding of resistance mechanisms is necessary to continue advancement in the field, said Corey J. Langer, MD. (here)

Innovent Provides Update on Phase Ib Study of Sintilimab in Combination with Chemotherapy for First-line Advanced or Metastatic Non-small Cell Lung Cancer (here)

Dr. Levy Discusses the Outlook for Oncogene-Driven NSCLC (here)